Despite that lack of knowledge, however, the demand for prophylactic bilateral mastectomy after first breast cancer is increasing not only for mutation carriers but also for women without a BRCA1 or BRCA2 mutation [14,15]. This evidence concerns the gene BRCA1 and breast carcinoma.